Back to Subject Index | Return to Arthritis & Rheumatism Table of Contents Page

D region
DNA binding of IgM[gl] anti-DNA antibody and, 389
genes, in RA, T cell receptors and, 577
DAB486IL-2, in refractory RA, 1177
Daudi target cells, 51Cr-labeled, cytolytic activity of polyclonal T cells in SLE and, 506
Debridement, in arthroscopic lavage in medical management of knee OA, 1541
Decorin
in articular cartilage in RA, 660
in OA, 525, 660
Deformed joints, work disability in RA and, 1630
Deforming arthritis, HLA type in MCTD and, 259
Degenerative joint diseases
guidelines for medical management of OA and, 1535, 1541
TGFβ1 in hyaluronan synthesis in synovial lining cells and, 669
Degenerative lumbar spinal stenosis, diagnosis of, 1236
Degenerative meniscal tears, monoclonal antibodies in detection of biochemical markers of, 655
Dehydrogenase, pyruvate, autoantibodies to, in SSc, 985
Delayed-type hypersensitivity, collagen type II in antigen-induced arthritis and, 1092
Deltoid muscle, in Lyme disease with DM symptoms in elderly,
1157
Dementia, multi-infarct, cognitive deficits in rheumatic diseases and, 1363
Demographic studies
in fibromyalgia, 19, 161, 229, 235
HLA antigens in disease progression in psoriatic arthritis, 845
hyaluronic acid and disease progression in knee OA, 760
NSAID-induced gastroduodenal injury in children and, 1225
occurrence of AS in twins in Finland, 381
pain in JRA and, 1142
in RA, 601, 642, 1115, 1120, 1194, 1204
in SLE, 267, 1475
walking velocity in elderly, 343
Denatured 52-kd molecule, autoepitopes of 52-kd SS-A/Ro and, 990
Denaturing gradient gel electrophoresis, COL2A1 gene mutations in chondrodysplasias and familial OA, 999
Dendritic cells, CD80 in RA and, 1863
Densitometry, bone, of hand, in RA, 1204
Deoxyglucose metabolism, MRI, PET and, in RA, 819
Deoxypyridinoline, steroids, hormone replacement and, in postmenopausal RA bone metabolism, 902
Depression
cognitive deficits in rheumatic diseases and, 1363
pain in JRA and, 1142
in RA, 49
Scale, of Center for Epidemiologic Studies, Spanish outcome measures and, 1429
in SLE, 827, 1475
Dermatologic vignette
acanthosis nigricans, 862
bullous rash and brown urine after hydroxychloroquine in SLE, 440
Dermatomyositis (DM)
functional disability in, 1218
immunosuppressive drugs during pregnancy and, 1722
juvenile, enteroviral RNA, bacterial DNA and, 1513
Mi-2 autoantigen in, 123, 1389
MRI/MRS in, 68
symptoms of, in Lyme disease in elderly, 1157
Dermis tissue in scleroderma in Tsk2 mouse, 1791
Desmosine, elastin and collagen degradation in SSc and, 517
Destructive septic polyarthritis, Ureaplasma urealyticum, common variable immunodeficiency and, 1524
Detritic synovitis, in loosening of revision total hip replacement in RA, 1315
Diabetes mellitus
ACR recommendations for liver biopsy after MTX in RA and, 1115
autoimmune disease induction by microbial pathogens and, 458
insulin-dependent, autoimmunity and, 301
risk factors for septic arthritis in joint disease and, 1819
Diagnosis-related group categories, cost of drugs in RA and, 318, 1862
Diagnostic use of office-based ultrasound, in Baker's cyst of right knee joint, 859
Diazepam, in Chinese herbal medications, 614
Dichlorofluorescein, peripheral blood neutrophils in Behcet's disease and, 426
Diclofenac
fish oil and, in RA, 1107
tenidap and, in experimental canine OA, 1290
Diet supplements, fish oil and NSAID in RA, 1107
Diffuse cognitive dysfunction, cognitive deficit in rheumatic diseases and, 1363
Diffuse cutaneous SSc
autoantibodies to pyruvate dehydrogenase in, 985
eosinophil major basic protein in, 939
guidelines for clinical trials in, 351
lipoprotein oxidation and, 1060
Diffuse idiopathic skeletal hyperostosis (DISH)
clinical image of, 1345
tracheal stenosis secondary to, 296
Diffuse neurologic involvement, acute, in spin-spin relaxation of brain tissue in SLE, 810
Digital ischemic attacks, in Raynaud's phenomenon and scleroderma, 1
Digoxigenin-labeled RNA probes, cathepsin, collagenase and, in RA and OA, 976
Dihydrofolate reductase, immunosuppressive drugs during pregnancy and, 1722
Diisopropylfluorophosphonate, rheumatoid synovial fibroblast adhesion in cartilage and, 1694
Diltiazem, in calcinosis, 1640
Dilution study, limiting, to study Klebsiella pneumoniae-reactive T cells in blood in AS, 1277
Dimethylmethylene blue dye-binding assay, in detection of stromelysin-cleaved rabbit aggrecan, 1400
Diphtheria fusion protein IL-2 (DAB486IL-2), in refractory RA, 1177
Dipyridamole, erythrocytes in rheumatoid vasculitis and, 248
Directed knee examination, cartilage abnormalities and, 917
Disability
cardiovascular fitness in end-stage OA and, 799
functional, 1142, 1218, 1555
index, in PM/DM, 1218
learning, cognitive deficits in rheumatic diseases and, 1363
prevalence and characteristics of fibromyalgia and, 19
in RA, 727, 1630
Scale, in Spanish outcome measures, 1429
in social and psychological impact of musculoskeletal conditions, 1351
Discoid LE, ear ulceration in, 1712
Disease activity
anti-U1 RNA antibodies in connective tissue disease and, 1837
in AS in twins in Finland, 381
autoimmune disease induction by microbial pathogens and, 458
cognitive deficits in rheumatic diseases and, 1363
evaluative laboratory testing and, 1555
hematology of Felty's syndrome and large granular lymphocytes and, 1252
IgG receptors in autoimmune disease and, 306
in JRA, 211, 715, 1531, 1735
measuring relevant change in, 1027
in pathogenesis of spondylarthropathies, 1547
in quantification of rheumatoid synovitis by MRI, 1604
quantitative bone scintigraphy in monostotic Paget's disease of bone and, 1506
in RA, 29, 44, 334, 601, 795, 819, 902, 969, 1031, 1107, 1187, 1204, 1466, 1865
serum soluble Fas/APO-1 in autoimmune disease and, 1738
in SLE, 506, 826, 1055, 1735, 1826
Disease activity (cont'd)
in SSc, 184, 351
sulfasalazine in spondylarthropathy and, 618
Disease duration
functional disability in PM/DM and, 1218
hematology of Felty's syndrome and large granular lymphocytes and, 1252
histologic findings in sacroiliitis in AS and, 499
hyaluronic acid, disease progression and, in knee OA, 760
joint space measurement in hand radiographs using computerized image analysis and, 891
in pediatric AS, 835
in RA, 44, 601, 1120, 1204
in SLE, 1475, 1492
Disease flares
autoimmune disease induction by microbial pathogens and, 458
cutaneous LE from photocopier emissions, 1152
dehydroepiandrosterone in SLE and, 1826
guidelines for medical management of OA and, 1535
MTX, prednisone and, in Wegener's granulomatosis, 608
in RA, 601, 1025, 1107, 1630
serum soluble Fas/APO-1 in autoimmune disease and, 1738
Disease-modifying anti-OA drugs, in medical management of OA, 1535
Disease-modifying antirheumatic drugs (DMARD) in RA
AIDS and, 1701
hand bone mineral density in, 1204
in medical management of knee OA, 1541
refractory, DAB486IL-2, 1177
tenidap and, 1447
Disease onset
adult respiratory distress syndrome, anti-Jo-1 antibody in PM and, 1519
in giant cell arteritis, infection and, 374
knee OA in the elderly and, 1500
in pediatric AS, 835
student's perspective on RA and, 315
Disease outcome
bone mineral density in RA and, 1204
draft guidelines for drugs in JRA clinical trials and, 715
evaluative laboratory testing and, 1555
hyaluronic acid, disease progression and, in knee OA, 760
Disease progression
Chlamydia trachomatis in synovial membranes and, 1410
functional disability in PM/DM and, 1218
HLA antigens in, in psoriatic arthritis, 845
mortality in SLE and, 1492
in OA, 760, 1500, 1535, 1541
in RA, 1194, 1466, 1799
soluble adhesion molecules, disease activity and, in SSc, 184
Disease remission
corticosteroids, pulse cyclophosphamide, plasma exchange and, in polyarteritis nodosa and Churg-Strauss syndrome, 1638
diltiazem in calcinosis and, 1640
drugs in autoimmunity and, 301
after MTX and prednisone in Wegener's granulomatosis, 608
in RA and AIDS, 1701
Disease severity
draft guidelines for drugs in JRA clinical trials and, 715
in fibromyalgia, 19, 161, 229, 235, 1211
HLA antigens in disease progression in psoriatic arthritis and, 845
in OA, 799, 1290, 1535, 1541
in RA, 649, 1344, 1630
Disease-susceptibility gene, inheritance of, in RA, 1754
Dismutase, superoxide, TGFβ1 in hyaluronan synthesis in synovial lining cells and, 669
Distal femur, in CPPD synovitis in rabbit OA, 201
Distal fibula, stress fractures in RA and, 1025
Distal radius, bone density, hip OA and, 907
Distal symmetric sensory or sensorimotor neuropathy, in necrotizing vasculitis in RA, 1618
Distal tibia, directed knee examination, cartilage abnormalities and, 917
Dizygotic twins, occurrence of AS in, in Finland, 381
DNA
autoimmune disease induction by microbial pathogens and, 458
bacterial, in juvenile DM, 1513
binding of, 389, 877
blood leukocyte, COL2A1 gene mutations in chondrodysplasias and familial OA, 999
cellular, 1771
chromosome Chlamydia, in reactive arthritis SF, 1005
complementary, 877, 1400, 1655
double-stranded, 190, 1068, 1485
fingerprinting, autoantibodies in SSc in twins and, 1845
HTLV-1 in PM and, 690
inheritance of HLA genes in RA and, 1754
in Lyme disease with DM symptoms in elderly, 1157
parvoviral, parvovirus B19 infection, chronic fatigue syndrome and, 638
in RA, 485, 577, 1771
sequence analysis, in detection of stromelysin-cleaved rabbit aggrecan, 1400
sequence homology, in anti-apolipoprotein A1 in SLE, 1655
synthesis, 960, 1722
typing, 755, 1832
Dolorimetry, prevalence and characteristics of fibromyalgia and, 19
Dorsal root ganglia, substance P and calcitonin gene-related peptide in rat adjuvant arthritis and, 699
Dot-blot assay, to study carbohydrates in RA immune complexes, 744
Dot-blot hybridization, to study inheritance of HLA genes in RA, 1754
Double staining, to study RA synovium, 678, 1762
Double-stranded DNA
antigen-based heteropolymers and, 190
human monoclonal antiphospholipid antibody and, 1068
nucleosome-restricted antibodies in SLE and, 1485
Doxycycline, Chlamydia trachomatis in synovial membranes and, 1410
DQB1
alleles, HRES-1 antibodies and, in SLE and overlap syndromes, 1660
MHC class II genes, anti-U1 snRNP antibody and, 396
DQw3, HLA antigens in disease progression in psoriatic arthritis and, 845
DR molecules, p4 peptide binding to DRB1*0401 and, 1744
DR1, inheritance of HLA genes in RA and, 1754
DR2, MHC class II genes, anti-U1 snRNP antibody and, 396
DR3, T cell receptors in RA and, 577
DR4
allele, inheritance of HLA genes in RA and, 1754
MHC class II genes, anti-U1 snRNP antibody and, 396
DR5, alleles, MHC class II genes, anti-U1 snRNP antibody and, 396
DR6, alleles, MHC class II genes, anti-U1 snRNP antibody and, 396
DR7, HLA antigens in disease progression in psoriatic arthritis and, 845
DR8
alleles, MHC class II genes, anti-U1 snRNP antibody and, 396
HLA-DR8 in acute anterior uveitis in AS and, 547
DRB1 in RA
alleles, 1754
HLA-Dw4 and, 298
inheritance of HLA genes and, 1754
DRB1*0404
allele, in gold-induced enterocolitis, 755
p4 peptide binding to, 1744
DRB1*1204, HLA-DR5 in primary antiphospholipid syndrome in a Mexican population, 1340
Drug abuse, sexual abuse, physical abuse and, in fibromyalgia, 161, 229, 235
Drugs
acetaminophen, 1535, 1541
alkylating agents, 1722
amitriptyline, 1211
analgesic, 5, 445, 1535, 1541
antibiotic, 361, 565, 1410
anti-CD4, 1457, 1581
anticoagulant, 5
anticytokine, 306
antiinflammatory, 715
antirheumatic, 242, 506, 715, 819, 1447
aspirin, 5
autoimmunity and, 301
azathioprine, 142, 506, 1722, 1799, 1851
benzodiazepines, 614
biologic, 715
bisphosphonate, 851
CAMPATH-1H, 254, 1589
capsaicin cream, 1541
chemotherapeutic, 1722
Chinese herbal medications, 614
chlorambucil, 1722
chloroquine, 334
chondroprotective, 1085
cimetidine, 5
clodronate, 1777
clomiphene, 1344
codeine, 1535
cognitive deficits in rheumatic diseases and, 1363
corticosteroid, 5, 434, 506, 902, 1218, 1348, 1638, 1722, 1826
cost of, in RA, 318, 1862
cyclophosphamide, 147, 608, 1120, 1639, 1722
cyclosporine, 446, 867, 1568, 1722
cytarabine, 1341
cytolytic activity of polyclonal T cells in SLE and, 506
cytotoxic, 506, 1722
dehydroepiandrosterone, 1826
diazepam, 614
diclofenac, 1107, 1290
dihydrofolate, 1722
diltiazem, 1640
dipyridamole, 248
disease-modifying anti-OA, 1535
DMARD, 1177, 1204, 1447, 1541, 1701
doxycycline, 1410
estrogen, 292
etidronate
experimental, 715
glucocorticoid, 819, 1722
gold, 242, 318, 1862
in guidelines for medical management of OA, 1535, 1541
hormone replacement, 902
hydroxychloroquine, 318, 440, 445, 1447, 1862
ibuprofen, 5
immunosuppressive, 565, 1333, 1341, 1722
intravenous immunoglobulin, 1722
leflunomide, 1595
leuprolide, 1722
L-tryptophan, 1363
mefenamic acid, 614
methylsalicylate, 1541
misoprostol, 5
MTX, 29, 291, 297, 318, 326, 575, 601, 608, 715, 819, 867, 874, 1014, 1040, 1173, 1194, 1348, 1528, 1581, 1799, 1861, 1862, 1865, 1866
naproxen, 5
Drugs (cont'd)
NSAID, 5, 105, 614, 618, 715, 723, 1107, 1225, 1447, 1535
omeprazole, 1290
oxycodone, 1535
pamidronate, 1506
penicillamine, 242, 318, 768, 1862
piroxicam, 5, 29, 1447
placebo, 5
plasma exchange, 1638
prednisone, 29, 334, 446, 608, 1225, 1638, 1722, 1826
prescription, in Chinese herbal medications, 614
prodrugs, 5
propoxyphene, 1535
risk factors for septic arthritis in joint disease and, 1819
SAARD, 96, 715, 1225, 1541
second-line, 318, 334, 1595, 1862
6-mercaptopurine, 1722
somatostatin, 1687
steroid, 902, 1348
sucralfate, 5
sulfasalazine, 573, 618
tenidap, 29, 1290, 1447
thiouric acid, 1722
tiludronate, 851
triamcinolone acetonide, 1687
2-chlorodeoxyadenosine, 1604
verapamil, 1640
zymosan, 164
Dual x-ray absorptiometry
in RA, 334, 806, 1204
to study environmental and genetic factors affecting bone mass, 61
to study steroids and hormone replacement in postmenopausal RA bone metabolism, 902
Duodenal injury, NSAID-induced gastroduodenal injury in children, 1225
Dysglobulinemia, biclonal, in spinal involvement in gout, 139
Dysmotility, esophageal, diltiazem in calcinosis and, 1640
Dyspepsia, NSAID, gastrointestinal tract and, 5